| Activation of IL-2 receptor alpha-chain gene by individual members of the rel oncogene family in association with serum response factor. | None |
| The v-Rel oncoprotein complexes with new Rel- and RelA-related proteins in transformed cells. | None |
| The v-Rel oncoprotein blocks apoptosis and proteolysis of I kappa B-alpha in transformed chicken spleen cells. | None |
| Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1. | None |
| Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids. | None |
| Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. | None |
| The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts. | None |
| Temperature-sensitive transforming mutants of the v-rel oncogene. | None |
| Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B. | None |
| The transcriptionally active factors mediating the effect of the HTLV-I Tax transactivator on the IL-2R alpha kappa B enhancer include the product of the c-rel proto-oncogene. | None |
| Cloning and transcription factor-binding sites of the human c-rel proto-oncogene promoter. | None |
| Basal phosphorylation of the PEST domain in the I(kappa)B(beta) regulates its functional interaction with the c-rel proto-oncogene product. | None |
| A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes. | None |
| ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. | None |
| Degradation of proto-oncoprotein c-Rel by the ubiquitin-proteasome pathway. | None |
| Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein. | None |